We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ACRS market cap is 171.32M. The company's latest EPS is USD -1.2387 and P/E is -1.90.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 9.28M | 17.57M | 2.4M | 2.77M | 4.35M |
| Operating Income | -29.88M | -30.35M | -16.13M | -12.66M | -9.67M |
| Net Income | -29.26M | -1.49M | -16.94M | -10.99M | -7.59M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 4.23M | 6.48M | 6.76M | 29.75M | 31.25M |
| Operating Income | -111.06M | -50.91M | -65.38M | -85.15M | -124.26M |
| Net Income | -161.35M | -51.02M | -90.87M | -86.91M | -88.48M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 218.35M | 197.41M | 174.07M | 161.07M | 182.39M |
| Total Liabilities | 62.02M | 40.23M | 32.05M | 27.25M | 52.24M |
| Total Equity | 156.33M | 157.18M | 142.01M | 133.82M | 130.15M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 98.3M | 70.78M | 251.21M | 254.6M | 197.41M |
| Total Liabilities | 28.39M | 33.13M | 53.87M | 56.98M | 40.23M |
| Total Equity | 69.91M | 37.65M | 197.34M | 197.62M | 157.18M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -71.56M | -78.33M | -20.82M | -33.14M | -11.14M |
| Investing | 38.67M | 46.22M | 16.83M | 16.16M | 18.95M |
| Financing | 26.66M | 26.71M | -55k | -66k | -44k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -96.45M | -38.63M | -52.13M | -67.57M | -78.33M |
| Investing | 105.68M | 6.39M | -167.63M | 12.63M | 46.22M |
| Financing | -30.32M | 18.37M | 225.05M | 72.87M | 26.71M |
| Market Cap | 171.32M |
| Price to Earnings Ratio | -1.90 |
| Price to Sales Ratio | 5.37 |
| Price to Cash Ratio | 4.21 |
| Price to Book Ratio | 1.07 |
| Dividend Yield | - |
| Shares Outstanding | 71.43M |
| Average Volume (1 week) | 616.2k |
| Average Volume (1 Month) | 923.73k |
| 52 Week Change | 91.87% |
| 52 Week High | 5.17 |
| 52 Week Low | 0.9515 |
| Spread (Intraday) | 0.18 (7.5%) |
| Company Name | Aclaris Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.aclaristx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
